Actos (pioglitazone) is a prescription medication used to lower blood sugar in adults with type 2 diabetes. It works alongside diet and exercise to help the body use insulin more effectively, and it’s typically prescribed when lifestyle changes alone aren’t enough to control blood sugar levels. Actos is not used for type 1 diabetes.
How Actos Works
Type 2 diabetes develops when the body’s cells stop responding well to insulin, a condition called insulin resistance. Actos belongs to a class of drugs called thiazolidinediones, which are insulin sensitizers. Rather than forcing the body to produce more insulin, Actos makes existing insulin work better by activating a receptor in cells that controls how the body processes sugar and fat.
When this receptor is switched on, cells throughout the body become more responsive to insulin and pull glucose out of the bloodstream more efficiently. Actos also reduces inflammation and improves how the body handles fats, lowering triglycerides and raising HDL (“good”) cholesterol. These effects take time to build. Most people notice meaningful blood sugar improvements over several weeks, not days.
How Much It Lowers Blood Sugar
Most people start Actos at 15 or 30 mg once daily, with a maximum dose of 45 mg. When paired with metformin in clinical studies, pioglitazone reduced HbA1c (a measure of average blood sugar over three months) by roughly 2.2 percentage points at 12 weeks and 2.8 points at 24 weeks. In one Korean study, patients on metformin plus pioglitazone saw their HbA1c drop from 9.0% to 6.6% over six months.
Those reductions are comparable to what other add-on medications achieve, though sulfonylureas (another common drug class) showed a slight edge over pioglitazone in one head-to-head comparison after adjusting for metformin dose. Actos is rarely used as a first-line treatment on its own. It’s more commonly added to metformin or other diabetes medications when a single drug isn’t achieving target blood sugar levels.
Use in Fatty Liver Disease
Beyond diabetes, pioglitazone has shown strong results for non-alcoholic steatohepatitis (NASH), a form of fatty liver disease that involves inflammation and can progress to scarring. This is currently an off-label use, meaning it’s not FDA-approved for this purpose, but clinical evidence supports it.
Pioglitazone was the first blood sugar medication shown in a randomized trial to reverse NASH. In the longest study to date, 51% of patients with prediabetes or type 2 diabetes who took pioglitazone for 18 months had their NASH resolve completely, compared to 19% on placebo. A meta-analysis of eight trials confirmed that pioglitazone nearly quadrupled the odds of NASH resolution and significantly improved liver scarring at any stage. The improvements are linked to pioglitazone’s ability to reduce visceral fat, lower free fatty acids in the blood, and increase adiponectin, a hormone that protects the liver.
Heart Failure Warning
Actos carries the FDA’s most serious warning, a boxed warning, for congestive heart failure. Thiazolidinediones cause the body to retain fluid, which can trigger or worsen heart failure in some patients. Signs to watch for include rapid weight gain, swelling in the legs or ankles, and shortness of breath, especially in the first weeks after starting the medication or after a dose increase.
Actos is not recommended for anyone with symptomatic heart failure, and it’s completely off-limits for people with moderate to severe heart failure (classified as NYHA Class III or IV). If you have any history of heart problems, your prescriber will weigh those risks carefully before starting this medication.
Bladder Cancer Risk
An FDA safety review confirmed that using pioglitazone for more than 12 months is associated with a small increased risk of bladder cancer, with the risk rising the longer the medication is taken. The updated prescribing label states that Actos should not be started in anyone with active bladder cancer and should be used cautiously in people with a history of it.
If you notice blood in your urine, a red or pink color when you urinate, or develop new urinary urgency or pain while taking Actos, those symptoms warrant prompt evaluation. The European Medicines Agency reviewed the same data and concluded that pioglitazone’s benefits still outweigh its risks for most patients, provided appropriate screening and monitoring are in place.
Bone Fracture Risk
Pioglitazone weakens bones over time, particularly in women. A large meta-analysis found that the drug increases overall fracture risk by about 21%, but the numbers vary significantly by sex and location. Women taking pioglitazone had a 56% higher fracture risk compared to controls, while men showed no statistically significant increase. Fractures of the lower extremities were 85% more likely, and spinal fractures more than doubled. Most of these fractures resulted from low-energy events like falls rather than major trauma.
This makes pioglitazone a less ideal choice for postmenopausal women or anyone already at elevated risk for osteoporosis. If you’re taking Actos long-term, bone density monitoring may be worth discussing.
Weight Gain and Fluid Retention
Weight gain is one of the most common side effects. It tends to be dose-dependent: around 1 to 2% of body weight at 15 mg daily, increasing to 3 to 5% at the highest dose of 45 mg. Part of this is true fat gain (often subcutaneous rather than visceral), and part is fluid retention. The fluid retention also contributes to swelling in the hands, feet, and ankles, which can be uncomfortable even in people without heart problems.
Who Should Not Take Actos
Three groups of people should avoid Actos entirely: those with moderate to severe heart failure, those with active bladder cancer, and anyone with a known allergy to pioglitazone or its inactive ingredients. People with a history of bladder cancer or unexplained blood in the urine need careful evaluation before starting. Liver function is typically checked before and periodically during treatment, as the earlier drug in this class (rosiglitazone) raised concerns about liver toxicity, though pioglitazone itself has a cleaner track record on that front.